We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




An Ultrasensitive Assay for Measurement of Levels of Cathepsin B in the Blood

By LabMedica International staff writers
Posted on 21 Apr 2021
A novel digital enzyme-linked immunosorbent assay (ELISA) has been developed for the differential detection of cathepsin B from samples of serum or plasma.

Cathepsin B (catB) is a lysosomal cysteine protease expressed in various cells and organs, where it plays a role in protein degradation and turnover. More...
Under pathological conditions, catB expression becomes upregulated in a variety of diseases including metastatic cancers, infections, traumatic brain injury, and neurological diseases. This upregulation is often associated with increased extracellular secretion via active or passive mechanisms. As such, the catB protein content is elevated above basal levels where it may have utility as a biofluid-based marker of diseases, injury, or trauma.

While biofluid samples such as plasma and serum contain catB, it is often difficult to obtain accurate measurements of the protein due to background interference and high variance, which limit the usefulness of catB as a peripheral biomarker. Thus, techniques for ultrasensitive protein detection that require low volumes of sample are necessary.

In this regard, investigators at Walter Reed Army Institute for Research (Silver Spring, MD, USA) developed a digital ELISA for differential detection of catB within less than five microliters of serum and plasma using the single molecule array (SiMoA) platform, which offers 1000-times more sensitivity and vastly reduced variance compared to colorimetric tests.

Results revealed that in buffer solution, the limit of detection (LoD) was between 1.56 and 8.47 picograms per milliliter depending on whether a two-step or three-step assay was used. After correcting for endogenous levels, the estimated LoD was approximately 4.7 picograms per milliliter in serum or plasma with the two-step assay. The lower limit of quantitation was about 2.3 picograms per milliliter in buffer and about 9.4 picograms per milliliter in serum or plasma, indicting the ability to measure small changes above endogenous levels within blood samples.

"Although cathepsin can be abundant in some tissues, accurate measurement in blood has been a challenge, especially if changes are expected to be small or sample is limited," said first author Dr. Bharani Thangavelu, a researcher in the brain trauma neuroprotection branch at the Walter Reed Army Institute for Research. "Our strategy uses an ultrasensitive technique to improve cathepsin B detection from small volumes of blood with little to no noise or impact from interfering substances."

The ultrasensitive ELISA for cathepsin B was described in the March 31, 2021, online edition of the journal ACS Omega.

Related Links:
Walter Reed Army Institute for Research


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.